Knecht Henrik, Neulinger Sven C, Heinsen Femke Anouska, Knecht Carolin, Schilhabel Anke, Schmitz Ruth A, Zimmermann Alexandra, dos Santos Vitor Martins, Ferrer Manuel, Rosenstiel Philip C, Schreiber Stefan, Friedrichs Anette K, Ott Stephan J
Institute of Clinical Molecular Biology (IKMB), Christian-Albrechts-University (CAU), Kiel, Germany.
Institute for General Microbiology (IFAM), Christian-Albrechts-University (CAU), Kiel, Germany.
PLoS One. 2014 Feb 28;9(2):e89417. doi: 10.1371/journal.pone.0089417. eCollection 2014.
Clostridium difficile infections are an emerging health problem in the modern hospital environment. Severe alterations of the gut microbiome with loss of resistance to colonization against C. difficile are thought to be the major trigger, but there is no clear concept of how C. difficile infection evolves and which microbiological factors are involved. We sequenced 16S rRNA amplicons generated from DNA and RNA/cDNA of fecal samples from three groups of individuals by FLX technology: (i) healthy controls (no antibiotic therapy); (ii) individuals receiving antibiotic therapy (Ampicillin/Sulbactam, cephalosporins, and fluoroquinolones with subsequent development of C. difficile infection or (iii) individuals receiving antibiotic therapy without C. difficile infection. We compared the effects of the three different antibiotic classes on the intestinal microbiome and the effects of alterations of the gut microbiome on C. difficile infection at the DNA (total microbiota) and rRNA (potentially active) levels. A comparison of antibiotic classes showed significant differences at DNA level, but not at RNA level. Among individuals that developed or did not develop a C. difficile infection under antibiotics we found no significant differences. We identified single species that were up- or down regulated in individuals receiving antibiotics who developed the infection compared to non-infected individuals. We found no significant differences in the global composition of the transcriptionally active gut microbiome associated with C. difficile infections. We suggest that up- and down regulation of specific bacterial species may be involved in colonization resistance against C. difficile providing a potential therapeutic approach through specific manipulation of the intestinal microbiome.
艰难梭菌感染是现代医院环境中一个新出现的健康问题。肠道微生物群的严重改变以及对艰难梭菌定植抵抗力的丧失被认为是主要触发因素,但对于艰难梭菌感染如何演变以及涉及哪些微生物学因素尚无明确概念。我们通过FLX技术对三组个体粪便样本的DNA和RNA/cDNA产生的16S rRNA扩增子进行了测序:(i)健康对照(未接受抗生素治疗);(ii)接受抗生素治疗的个体(氨苄西林/舒巴坦、头孢菌素和氟喹诺酮,随后发生艰难梭菌感染)或(iii)接受抗生素治疗但未发生艰难梭菌感染的个体。我们比较了三种不同抗生素类别对肠道微生物群的影响以及肠道微生物群改变对艰难梭菌感染在DNA(总微生物群)和rRNA(潜在活性)水平的影响。抗生素类别的比较在DNA水平显示出显著差异,但在RNA水平没有。在接受抗生素治疗后发生或未发生艰难梭菌感染的个体中,我们未发现显著差异。我们确定了在发生感染的接受抗生素治疗的个体中与未感染个体相比上调或下调的单一物种。我们发现与艰难梭菌感染相关的转录活性肠道微生物群的整体组成没有显著差异。我们认为特定细菌物种的上调和下调可能参与对艰难梭菌的定植抵抗,通过对肠道微生物群的特定操纵提供了一种潜在的治疗方法。